Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BDRX | EFFECT | bearish | 6/10 | The SEC declared effective Biodexa Pharmaceuticals' F-1 registration statement (File No. 333-299106) on September 30, 20 | Oct 1, 2026 |
| VVOS | 8-K | bearish | 6/10 | Vivos Therapeutics dismissed Baker Tilly US, LLP as its independent auditor and engaged Haynie & Company, a smaller firm | Sep 30, 2026 |
| IDXG | S-1/A | neutral | 5/10 | Interpace Biosciences is filing Amendment No. 1 to its S-1 registration statement for a firm-commitment IPO of 3,100,000 | Sep 30, 2026 |
| INDV | SC 13G | neutral | 4/10 | Millennium Management LLC disclosed a 5.4% passive stake in Indivior Pharmaceuticals via a Schedule 13G filed September | Sep 30, 2026 |
| STOK | SC 13G | neutral | 4/10 | Biotechnology Value Fund L.P. (BVF) and related entities filed a new Schedule 13G disclosing a 5.6% beneficial ownership | Sep 30, 2026 |
| ADIL | PRESS-RELEASE | neutral | 2/10 | Adial Pharmaceuticals granted a new employee stock option to purchase 155,446 shares at $4.22 as an inducement for hirin | Sep 30, 2026 |
| AKAN | 6-K | bearish | 7/10 | Akanda Corp. filed its H1 2026 6-K, reporting a net loss of $6.2M vs $815K in H1 2025, driven by a massive increase in g | Sep 30, 2026 |
| LQDA | 8-K | bearish | 7/10 | The District Court ruled that two of six patent claims asserted by United Therapeutics against Liquidia's YUTREPIA are v | Sep 30, 2026 |
| ADRX | CLUSTER | bullish | 7/10 | Director and 10% owner George Simeon made two large open-market purchases totaling ~$17.1M at $17/share, while another 1 | Sep 30, 2026 |
| IMMX | 8-K | bearish | 6/10 | Immix Biopharma priced a $125 million underwritten offering of 11,363,637 shares at $11.00 per share, with net proceeds | Sep 30, 2026 |
| PRTA | INSIDER-BUY | bullish | 5/10 | 10% owner William P. Scully purchased 265,500 shares of Prothena for ~$2.30M in open-market transactions on September 28 | Sep 30, 2026 |
| PTPI | 8-K | bearish | 9/10 | Petros Pharmaceuticals has entered into a General Assignment for the Benefit of Creditors (ABC) under California law, ef | Sep 30, 2026 |
| SPRC | 6-K | bearish | 6/10 | SciSparc filed its H1 2026 interim financials, reporting a net loss of $6.1M (improved from $9.4M in H1 2025) on revenue | Sep 30, 2026 |
| OCS | 6-K | neutral | 2/10 | Oculis Holding AG announced the resignation of director Lionel Carnot from its Board of Directors, effective September 3 | Sep 30, 2026 |
| TCRX | 8-K | neutral | 2/10 | TScan Therapeutics formalized separation agreements with former CFO Jason Amello and former CMO Chrystal Louis, previous | Sep 30, 2026 |
| CRBP | SC 13G | neutral | 4/10 | RA Capital Management, L.P. and affiliated entities filed a Schedule 13G disclosing a 9.9% passive stake in Corbus Pharm | Sep 30, 2026 |
| BSEM | 8-K | bearish | 6/10 | BioStem Technologies raised approximately $3.0 million in a private placement priced at-the-market under Nasdaq rules, i | Sep 30, 2026 |
| TVGN | 8-K | neutral | 4/10 | Tevogen Inc. received written notice from Nasdaq on September 29, 2026, confirming it regained compliance with the $50 m | Sep 30, 2026 |
| KOD | SC 13D/A | bullish | 7/10 | Baker Bros. Advisors LP filed Amendment No. 12 to its Schedule 13D for Kodiak Sciences Inc., reporting a massive open-ma | Sep 30, 2026 |
| TEVA | PRESS-RELEASE | neutral | 2/10 | TAPI, a subsidiary of Teva Pharmaceutical Industries, appointed Serge Rogasik as its new CEO. Rogasik brings over 25 yea | Sep 30, 2026 |
| BNTC | 8-K | neutral | 3/10 | Benitec Biopharma filed an 8-K confirming the engagement of Ernst & Young (EY) as its independent auditor for FY2027, fo | Sep 30, 2026 |
| MLYS | 144 | neutral | 3/10 | Director Jon Congleton filed a Form 144 notice of intent to sell 75,000 shares of Mineralys Therapeutics common stock, w | Sep 30, 2026 |
| CALC | 8-K | bearish | 5/10 | CalciMedica filed a prospectus supplement to sell up to $25 million of common stock under an existing at-the-market offe | Sep 30, 2026 |
| CMMB | 6-K | neutral | 4/10 | Chemomab filed a 6-K reporting a technical amendment to its Domestication Merger Agreement with Scipher Medicine. The am | Sep 30, 2026 |
| CALC | 424B5 | bearish | 5/10 | CalciMedica filed a 424B5 prospectus supplement to sell up to $25 million of common stock via an at-the-market (ATM) off | Sep 30, 2026 |
| LTRN | 8-K | bearish | 6/10 | Lantern Pharma entered into a securities purchase agreement to sell approximately $4 million of common stock and pre-fun | Sep 30, 2026 |
| AIM | DEF 14A | neutral | 3/10 | AIM ImmunoTech Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for Nove | Sep 30, 2026 |
| CRVS | PRESS-RELEASE | neutral | 3/10 | Corvus Pharmaceuticals announced the initiation of a Phase 1b trial of soquelitinib for hidradenitis suppurativa, a chro | Sep 30, 2026 |
| GLUE | PRESS-RELEASE | neutral | 5/10 | Monte Rosa Therapeutics announced a conference call and webcast to review clinical results from the GFORCE-1 Phase 1 stu | Sep 30, 2026 |
| ABPO | 25-NSE | bearish | 9/10 | Nasdaq has filed Form 25-NSE to remove Abpro Holdings, Inc. from listing, effective October 12, 2026, after a year-long | Sep 30, 2026 |